









Markets
/
Stocks
/
nasdaq-nams
/

NewAmsterdam Pharma Company NV

NAMS

View Detailed Chart

21.280USD

-0.530-2.43%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

2.39BMarket Cap

LossP/E TTM



NewAmsterdam Pharma Company NV

21.280

-0.530-2.43%

Overview Company Financials

Financials

Intraday

30m

Today

-2.43%

5 Days

-9.83%

1 Month

+7.20%

6 Months

-0.37%

Year to Date

-17.20%

1 Year

+25.03%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 14 analysts

BUY

Current Rating

42.417

Target Price

99.33%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

NewAmsterdam Pharma Company NV

NAMS

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(5)

Neutral(3)

Buy(3)

Indicators

Sell(2)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.392

Neutral

RSI(14)

48.309

Neutral

STOCH(KDJ)(9,3,3)

15.001

Sell

ATR(14)

1.227

Low Volatility

CCI(14)

-94.659

Neutral

Williams %R

82.494

Oversold

TRIX(12,20)

0.711

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

22.344

Sell

MA10

22.818

Sell

MA20

22.058

Sell

MA50

20.150

Buy

MA100

19.754

Buy

MA200

20.813

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.

Ticker SymbolNAMS

CompanyNewAmsterdam Pharma Company NV

CEODr. Michael Harvey Davidson, M.D.

Websitehttps://ir.newamsterdampharma.com/